Incyte Corporation INCY
Verdict: Sell. Fair value $105 against a price of $102 on 6 Jan 2026, 3% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has shown extreme volatility, collapsing 95% from $0.60B in 2023 to $0.03B in 2024. The.... Operating Cash Flow has declined for two consecutive years, falling from a high of $0.97B in 2022....
Main risks
- Severe Net Income Collapse: Annual net income plummeted 95% from $0.60B in 2023 to just $0.03B in 2024, crushing accounting-based returns (ROE, ROA) and raising major questions about profitability drivers or large one-off expenses.
- Divergence of Net Income and Cash Flow: The massive gap between TTM Free Cash Flow ($1.17B) and 2024 Net Income ($0.03B) is a significant red flag. This divergence suggests large non-cash charges (e.g., impairments, stock-based compensation) are obscuring the company's true earnings power.
- Deteriorating Annual Free Cash Flow: Despite a strong TTM figure, the annual FCF trend is negative, falling from a high of $0.89B in 2022 to $0.24B in 2024, a 73% decline. This warrants skepticism about the sustainability of the TTM performance.
- Net Income has shown extreme volatility, collapsing 95% from $0.60B in 2023 to $0.03B in 2024. The...
- Operating Cash Flow has declined for two consecutive years, falling from a high of $0.97B in 2022...
- Intense competitive environment